PYC Therapeutics shares progress with its investigational drug candidate, VP-001, for treating Retinitis Pigmentosa type 11, a blinding eye disease in children, to mid-stage human trials.
Following a positive review from the safety review committee, which assessed the safety and tolerability of three different doses in patient cohorts, the company is set to initiate a multiple ascending dose study and continue dose escalation in the single ascending dose study to maximise patient benefit before beginning registrational trials.
The multiple ascending dose study, scheduled to start in the second quarter, aims to provide further insights into the efficacy and extended exposure effects of VP-001 on the retina of RP11 patients.